EGFR bispecific antibody armed activated T-cells

EGFR bispecific antibody armed activated T-cells (EGFR BATs) is an autologous cell-based immunotherapy developed by Memorial Sloan Kettering Cancer Center for the treatment of advanced pancreatic adenocarcinoma. The production process involves harvesting a patient's peripheral blood mononuclear cells, which are then activated and expanded ex vivo using anti-CD3 monoclonal antibodies and interleukin-2 (IL-2). These activated T cells (ATC) are subsequently "armed" by coating them with a bispecific antibody (BiAb) that targets both CD3 on the T cells and the epidermal growth factor receptor (EGFR) overexpressed on pancreatic cancer cells. This approach effectively turns the T cells into targeted cytotoxic effectors that can recognize and kill EGFR-positive tumor cells without requiring MHC restriction. Early clinical studies have evaluated the safety and efficacy of these cells in patients who have progressed on standard chemotherapy.

Other names

Anti-CD3 x Anti-EGFR-bispecific antibody armed activated T-cellsAnti-CD-3 x Anti-EGFR-bispecific antibody armed activated T-cellsAnti-CD 3 x Anti-EGFR-bispecific antibody armed activated T-cellsEGFRBi-armed activated T cellsEGFR-bispecific antibody armed activated T-cells